Genentech AVAiL Trial Results May Lower Avastin Dosing In NSCLC
Executive Summary
Findings that a lower dose of Genentech's Avastin showed a similar treatment effect on progression-free survival as a higher dose in the AVAiL trial in first-line non-small cell lung cancer could impact physician prescribing patterns for the oncologic in lung cancer
You may also be interested in...
One Cost Of Cancer: The Rising Price Of Treatment
Given the debate surrounding the country's soaring health care costs, it's no surprise that cancer medicines - and their escalating prices - are coming under attack
One Cost Of Cancer: The Rising Price Of Treatment
Given the debate surrounding the country's soaring health care costs, it's no surprise that cancer medicines - and their escalating prices - are coming under attack
One Cost Of Cancer: The Rising Price Of Treatment
Cancer therapies hit 5 percent of total drug spending for the first time in first half of 2009, Medco says